Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats

William Kielbasa, J. Cory Kalvass, Robert Stratford Jr.

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

A comprehensive in vivo evaluation of brain penetrability and central nervous system (CNS) pharmacokinetics of atomoxetine in rats was conducted using brain microdialysis. We sought to determine the nature and extent of transport at the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCB) and to characterize brain extracellular and cellular disposition. The steady-state extracellular fluid (ECF) to plasma unbound (uP) concentration ratio (C ECF/CuP = 0.7) and the cerebrospinal fluid (CSF) to plasma unbound concentration ratio (CCSF/CuP = 1.7) were both near unity, indicating that atomoxetine transport across the BBB and BCB is primarily passive. On the basis of the ratios of whole brain concentration to CESF (CB/C<ECF = 170), brain cell (BC) concentration to cESF (cBC/cESF = 219), and unbound brain cell concentration to cESF (CUBC/c ECF = 2.9), we conclude that whole brain concentration does not represent the concentration in the biophase and atomoxetine primarily partitions into brain cells. The distributional clearance at the BBB (QBBB = 0.00110 l/h) was estimated to be 12 times more rapid than that at the BCB [QBCB = 0.0000909 l/h) and similar to the clearances across brain parenchyma (CLECF-BC = 0.00216 l/h; CLBC-ECF = 0.000934 l/h). In summary, the first detailed examination using a quantitative microdialysis technique to understand the brain disposition of atomoxetine was conducted. We determined that atomoxetine brain penetration is high, movements across the BBB and BCB occur predominantly by a passive mechanism, and rapid equilibration of ECF and CSF with plasma occurs.

Original languageEnglish (US)
Pages (from-to)137-142
Number of pages6
JournalDrug Metabolism and Disposition
Volume37
Issue number1
DOIs
StatePublished - Jan 1 2009
Externally publishedYes

Fingerprint

Microdialysis
Central Nervous System
Pharmacokinetics
Extracellular Fluid
Brain
Cerebrospinal Fluid
Blood-Brain Barrier
Atomoxetine Hydrochloride

ASJC Scopus subject areas

  • Pharmacology
  • Pharmaceutical Science

Cite this

Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats. / Kielbasa, William; Kalvass, J. Cory; Stratford Jr., Robert.

In: Drug Metabolism and Disposition, Vol. 37, No. 1, 01.01.2009, p. 137-142.

Research output: Contribution to journalArticle

@article{5b8bf712e80e4af9baac8f6832d35ab1,
title = "Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats",
abstract = "A comprehensive in vivo evaluation of brain penetrability and central nervous system (CNS) pharmacokinetics of atomoxetine in rats was conducted using brain microdialysis. We sought to determine the nature and extent of transport at the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCB) and to characterize brain extracellular and cellular disposition. The steady-state extracellular fluid (ECF) to plasma unbound (uP) concentration ratio (C ECF/CuP = 0.7) and the cerebrospinal fluid (CSF) to plasma unbound concentration ratio (CCSF/CuP = 1.7) were both near unity, indicating that atomoxetine transport across the BBB and BCB is primarily passive. On the basis of the ratios of whole brain concentration to CESF (CB/C<ECF = 170), brain cell (BC) concentration to cESF (cBC/cESF = 219), and unbound brain cell concentration to cESF (CUBC/c ECF = 2.9), we conclude that whole brain concentration does not represent the concentration in the biophase and atomoxetine primarily partitions into brain cells. The distributional clearance at the BBB (QBBB = 0.00110 l/h) was estimated to be 12 times more rapid than that at the BCB [QBCB = 0.0000909 l/h) and similar to the clearances across brain parenchyma (CLECF-BC = 0.00216 l/h; CLBC-ECF = 0.000934 l/h). In summary, the first detailed examination using a quantitative microdialysis technique to understand the brain disposition of atomoxetine was conducted. We determined that atomoxetine brain penetration is high, movements across the BBB and BCB occur predominantly by a passive mechanism, and rapid equilibration of ECF and CSF with plasma occurs.",
author = "William Kielbasa and Kalvass, {J. Cory} and {Stratford Jr.}, Robert",
year = "2009",
month = "1",
day = "1",
doi = "10.1124/dmd.108.023119",
language = "English (US)",
volume = "37",
pages = "137--142",
journal = "Drug Metabolism and Disposition",
issn = "0090-9556",
publisher = "American Society for Pharmacology and Experimental Therapeutics",
number = "1",

}

TY - JOUR

T1 - Microdialysis evaluation of atomoxetine brain penetration and central nervous system pharmacokinetics in rats

AU - Kielbasa, William

AU - Kalvass, J. Cory

AU - Stratford Jr., Robert

PY - 2009/1/1

Y1 - 2009/1/1

N2 - A comprehensive in vivo evaluation of brain penetrability and central nervous system (CNS) pharmacokinetics of atomoxetine in rats was conducted using brain microdialysis. We sought to determine the nature and extent of transport at the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCB) and to characterize brain extracellular and cellular disposition. The steady-state extracellular fluid (ECF) to plasma unbound (uP) concentration ratio (C ECF/CuP = 0.7) and the cerebrospinal fluid (CSF) to plasma unbound concentration ratio (CCSF/CuP = 1.7) were both near unity, indicating that atomoxetine transport across the BBB and BCB is primarily passive. On the basis of the ratios of whole brain concentration to CESF (CB/C<ECF = 170), brain cell (BC) concentration to cESF (cBC/cESF = 219), and unbound brain cell concentration to cESF (CUBC/c ECF = 2.9), we conclude that whole brain concentration does not represent the concentration in the biophase and atomoxetine primarily partitions into brain cells. The distributional clearance at the BBB (QBBB = 0.00110 l/h) was estimated to be 12 times more rapid than that at the BCB [QBCB = 0.0000909 l/h) and similar to the clearances across brain parenchyma (CLECF-BC = 0.00216 l/h; CLBC-ECF = 0.000934 l/h). In summary, the first detailed examination using a quantitative microdialysis technique to understand the brain disposition of atomoxetine was conducted. We determined that atomoxetine brain penetration is high, movements across the BBB and BCB occur predominantly by a passive mechanism, and rapid equilibration of ECF and CSF with plasma occurs.

AB - A comprehensive in vivo evaluation of brain penetrability and central nervous system (CNS) pharmacokinetics of atomoxetine in rats was conducted using brain microdialysis. We sought to determine the nature and extent of transport at the blood-brain barrier (BBB) and blood-cerebrospinal fluid barrier (BCB) and to characterize brain extracellular and cellular disposition. The steady-state extracellular fluid (ECF) to plasma unbound (uP) concentration ratio (C ECF/CuP = 0.7) and the cerebrospinal fluid (CSF) to plasma unbound concentration ratio (CCSF/CuP = 1.7) were both near unity, indicating that atomoxetine transport across the BBB and BCB is primarily passive. On the basis of the ratios of whole brain concentration to CESF (CB/C<ECF = 170), brain cell (BC) concentration to cESF (cBC/cESF = 219), and unbound brain cell concentration to cESF (CUBC/c ECF = 2.9), we conclude that whole brain concentration does not represent the concentration in the biophase and atomoxetine primarily partitions into brain cells. The distributional clearance at the BBB (QBBB = 0.00110 l/h) was estimated to be 12 times more rapid than that at the BCB [QBCB = 0.0000909 l/h) and similar to the clearances across brain parenchyma (CLECF-BC = 0.00216 l/h; CLBC-ECF = 0.000934 l/h). In summary, the first detailed examination using a quantitative microdialysis technique to understand the brain disposition of atomoxetine was conducted. We determined that atomoxetine brain penetration is high, movements across the BBB and BCB occur predominantly by a passive mechanism, and rapid equilibration of ECF and CSF with plasma occurs.

UR - http://www.scopus.com/inward/record.url?scp=58149467009&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=58149467009&partnerID=8YFLogxK

U2 - 10.1124/dmd.108.023119

DO - 10.1124/dmd.108.023119

M3 - Article

VL - 37

SP - 137

EP - 142

JO - Drug Metabolism and Disposition

JF - Drug Metabolism and Disposition

SN - 0090-9556

IS - 1

ER -